{
  "docId": "019dd923-622b-71dc-a6da-84595e2c37a3",
  "docSlug": "08680a75fcb3",
  "documentTitle": "Pfizer Inc. (PFE)",
  "authorId": "03_Starboard_Value",
  "authorName": "Starboard Value",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2024-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 43,
  "pageCount": 74,
  "prevPage": 42,
  "nextPage": 44,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "overcrowded",
  "nDataPoints": 5,
  "notes": "The slide uses a stacked bar chart to visualize the revenue gap and contribution from various acquisitions.",
  "elementsJson": [
    "headline_text",
    "screenshot",
    "bar_chart_stacked",
    "callout_box"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/43",
  "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3",
  "deckJsonHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3.json",
  "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-43",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.15,
        "x": 0.15,
        "y": 0.4
      },
      "kind": "callout",
      "text": "The Company spent nearly $70 billion on M&A at an implied ~3.3x \"peak\" revenue multiple",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9b44fdf3-6490-4663-a0cc-9dd2ccf9e746",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "callout",
      "text": "The Company spent nearly $70 billion on M&A at an implied ~3.3x “peak” revenue multiple",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-e6eb-753a-a395-32c8d48625d4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.44,
        "x": 0.28,
        "y": 0.23
      },
      "kind": "chart",
      "text": "Stacked bar chart showing 2030 potential risk adjusted revenues",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0195baf8-4f30-40f5-8a50-a82787958983",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "2030 revenue: $20.5B",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-e6eb-753a-a395-3b1358843b63",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "Completed deals + Seagen have the potential to contribute >$20.5B — Pfizer Public Presentation",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd952-e6eb-753a-a395-3731a46a9a11",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.35,
        "y": 0.18
      },
      "kind": "source-note",
      "text": "Excerpt from Pfizer Public Presentation",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6ea3641f-76bf-4f22-bbdd-6d9fe7c267dd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "title",
      "text": "Pfizer management expects these transactions to contribute >$20.5 billion in revenue by 2030.",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f05297b-6d8a-4c51-a97f-61aecf3cc19f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "The Company Expects Its Acquisitions Since 2022 to Generate >$20.5 Billion in Sales by 2030",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fec5efc6-8a20-42f2-a668-f6109228c4cb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "expose_contradiction",
      "slug": null,
      "matchId": "5b7f3918-d158-4f5b-9750-eec3fa6d7ff0",
      "evidence": "The slide contrasts the high cost of acquisitions ($70B) with the projected revenue contribution ($20.5B) to imply poor capital allocation.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 73,
      "from": 10,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07",
      "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.",
      "position": 0,
      "objective": "What are the costs of inaction for Pfizer?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 71,
      "from": 11,
      "name": "Mece Breakdown",
      "slug": "40-mece-breakdown",
      "bestFor": "Problem structuring, ensuring completeness, strategic analysis",
      "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f",
      "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.",
      "position": 1,
      "objective": "How can Pfizer improve its performance?",
      "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage",
      "confidence": 0.7,
      "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}